| Name | Zotepine |
| Description | Zotepine, an antipsychotic agent, is a potent antagonist of 5-HT2A, 5-HT2C, Histamine H1, α1-adrenergic, and Dopamine D2 receptors, with Kds of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively. This second-generation antipsychotic is primarily used to treat schizophrenia, and clinical trials have investigated its efficacy as an antimanic agent in patients with acute bipolar mania. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.03 mM), Sonication is recommended. DMSO : 25 mg/mL (75.33 mM), Sonication is recommended.
|
| Keywords | α1-adrenergic receptor | Zotepine | Serotonin Receptor | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H1 receptor | DopamineReceptor | Dopamine Receptor | D2 | Beta Receptor | anxiolytic | antipsychotic | antidepressive | AdrenergicReceptor | Adrenergic Receptor | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT2C | 5-HT2A | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Undecane | Alverine citrate | Meclizine dihydrochloride | Dapoxetine hydrochloride | Cefaclor monohydrate | Hexamethonium Bromide | Famotidine | 1,8-Cineole | Sodium butanoate | D-Mannitol | Alginic acid | Cinchonidine |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |